Developing new drugs is one of the most challenging and costly processes in medical science. This issue is exacerbated by the fact that traditional research and development methods are often ineffective and time-consuming. However, a new collaboration between Absci and Memorial Sloan Kettering Cancer Center (MSK) promises to transform the way we create medicines.
A Rethought Approach to Antibody Development
Absci, a leader in generative artificial intelligence (AI) for drug creation, offers a radically new approach to antibody development. Unlike traditional methods that use existing antibody libraries and make incremental improvements, Absci designs antibodies “from scratch” using AI. This means they can create unique candidate molecules not found in existing databases and test them in the lab without lengthy and costly optimization steps.
Overcoming Challenges in Traditional Drug Discovery
Traditional methods for biologics drug discovery are characterized by high risk, long timelines, and significant costs. Statistics show that over 90% of new drug development projects fail. Absci provides a solution that allows for not just searching for a needle in a haystack but creating the needle itself. With their new Integrated Drug Creation™ platform, they can accelerate the development process and increase the likelihood of success.
Absci’s Innovative Platform
Absci’s Integrated Drug Creation™ platform combines AI with synthetic biology to overcome the limitations of traditional drug discovery methods. It enables the creation and testing of millions of unique designs every week, with lab data quickly fed back into the development process. This creates a cycle where the time from design to data can be as short as six weeks, significantly speeding up the journey from concept to potential drug.
Collaboration with MSK: A Step Towards Oncology Breakthroughs
The new partnership between Absci and Memorial Sloan Kettering Cancer Center marks a significant advancement. Using Absci’s platform and MSK’s deep understanding of oncology, the partnership aims to develop up to six new cancer therapies. This collaboration combines cutting-edge technology with expert knowledge, promising to accelerate the discovery and development of effective treatments.
The Future of Drug Development
This partnership highlights the immense potential of applying AI in medicine. Absci, already successful with partnerships with companies like AstraZeneca and Almirall and its own developments like the anti-TL1A antibody, continues to broaden its horizons. Their goal is not only to enhance existing treatments but also to uncover new possibilities in combating cancer and other difficult-to-treat diseases.
The Absci and MSK partnership is a prime example of how innovative technologies can transform medical science. With their help, we can look forward to faster, more effective, and accessible treatment methods, ultimately revolutionizing the approach to fighting serious diseases.
Sources:
- https://www.mskcc.org/
- https://www.absci.com/https://hitconsultant.net/2024/08/12/absci-msk-generative-ai-drug-discovery/
- https://hitconsultant.net/tag/artificial-intelligence/
- https://www.absci.com/technology/
- https://www.istockphoto.com/fr/search/2/image-film?phrase=medical&page=2
A propos de Farangiz ASKHANOVA
Master 2 E-commerce à l'Université de Strasbourg, Faculté de Droit de sciences politiques et de gestion
